ORAGENICS INC
About ORAGENICS INC
Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2023
- $37.7K
- Net income
- -$9.8M
- Total assets
- $10.1M
- Market cap
- $2.7M
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $9.4M
- Operating income
- -$9.4M
- Net income
- -$9.8M
- EPS (basic)
- $-4.56
- EPS (diluted)
- $-4.56
Balance sheet
- Total assets
- $10.1M
- Current assets
- $10.1M
- Total liabilities
- $1.8M
- Current liabilities
- $1.8M
- Shareholders’ equity
- $8.3M
Cash flow
- Operating cash flow
- -$9.2M
- Investing cash flow
- -$7.5M
- Financing cash flow
- $16.8M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
- Market cap
- $2.7M
- EPS (diluted)
- $-4.56
- Shares outstanding
- 4.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 3, 2003
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $9.8M in FY2023.
- Trading 90% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ORAGENICS INC.
Write a review
News about ORAGENICS INC
News & sentiment via Polygon.io
